You are here

Keytruda

The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017

The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017

Motley Fool

cancer immunotherapies

Bristol-Myers Squibb

Flag link:

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

Endpoints

clinical trials

Flag link:

Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?

Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?

Motley Fool

Bristol-Myers Squibb

Flag link:

Cancer patients know immuno-oncology and top drugs, but lack details: study

Cancer patients know immuno-oncology and top drugs, but lack details: study

Fierce Pharma

immuno-oncology

Bristol-Myers Squibb

Flag link:

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

Fierce Pharma

Flag link:

ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer

ESMO: Merck piles on the positive Keytruda-chemo combo results in lung cancer

Fierce Pharma

Flag link:

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials

FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials

RAPS.org

Multiple Myeloma

Flag link:

Incyte’s good week continues with an encouraging update on IDO1 star epacadostat

Incyte’s good week continues with an encouraging update on IDO1 star epacadostat

Endpoints

Flag link:

Incyte, Merck build case for skin cancer combo

Incyte, Merck build case for skin cancer combo

BioPharma Dive

advanced melanoma

Flag link:

Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo

Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo

Motley Fool

Bristol-Myers Squibb

Flag link:

Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval

Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval

Fierce Pharma

Bristol-Myers Squibb

colorectal cancer

Flag link:

Keytruda keeps on climbing for Merck as other PD-1s flounder

Keytruda keeps on climbing for Merck as other PD-1s flounder

BioPharma Dive

Flag link:

The Startling History Behind Merck's New Cancer Blockbuster

The Startling History Behind Merck's New Cancer Blockbuster

Forbes

Flag link:

Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer

Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer

Xconomy

head and neck cancer

Flag link:

Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending

Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending

Fierce Pharma

non-small cell lung cancer

Flag link:

FDA Considers Label Changes for Keytruda, Opdivo and Yervoy

FDA Considers Label Changes for Keytruda, Opdivo and Yervoy

RAPS.org

immuno-oncology

Bristol-Myers Squibb

Flag link:

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now

Motley Fool

Bristol-Myers Squibb

Flag link:

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

What the FDA's Hold on Three Merck Studies Means for Other Drug Makers

TheStreet.com

clinical trials

Multiple Myeloma

Bristol-Myers Squibb

Flag link:

Prescribed Reading: I/O is the only game in town

Prescribed Reading: I/O is the only game in town

BioPharma Dive

immuno-oncology

Endo International

Vertex Pharmaceuticals

Bristol-Myers Squibb

Flag link:

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

Endpoints

clinical trials

Multiple Myeloma

Flag link:

Pages